Searched for: in-biosketch:true
person:yazicy01
Analysis Of The JAK1 Selectivity Of GLPG0634 and Its Main Metabolite In Different Species, Healthy Volunteers and Rheumatoid Arthritis Patients [Meeting Abstract]
Fleischmann, R. ; Schiff, M. ; Weinblatt, M. E. ; Maldonado, M. ; Massarotti, E. ; Yazici, Y.
ISI:000325359201475
ISSN: 0004-3591
CID: 657442
Tobacco Exposure Is Associated With Radiographic Damage In Hispanic and African American Rheumatoid Arthritis Patients [Meeting Abstract]
Alamino, Rodolfo Perez ; Espinoza, Luis R. ; Kerr, Gail S. ; Swearingen, Christopher ; Luo, Chunqiao ; Yazici, Yusuf ; Sherrer, Yvonne R. S. ; Treadwell, Edward L. ; Mosley-Williams, Angelia D. ; Dowell, Sharon ; Garcia-Valladares, Ignacio ; Lawrence-Ford, Theresa ; Godoy, Adrian ; Ince, Akgun ; Flower, Cindy
ISI:000325359203295
ISSN: 0004-3591
CID: 657372
Disparity In Biologic Therapy In Ethnic Minorities With Rheumatoid Arthritis: Can It All Be Due To Lack Of Access To Drug? [Meeting Abstract]
Kerr, Gail S. ; Mikuls, Ted R. ; Swearingen, Christopher J. ; Luo, Chunqiao ; Yazici, Yusuf
ISI:000325359204173
ISSN: 0004-3591
CID: 657272
Less Than 5% Of Ethnic Minority Rheumatoid Arthritis Patients Meet Inclusion Criteria For Randomized Controlled Clinical Trials [Meeting Abstract]
Kerr, Gail S. ; Yazici, Yusuf ; Swearingen, Christopher ; Luo, Chunqiao ; Sherrer, Yvonne R. S. ; Treadwell, Edward L. ; Mosley-Williams, Angelia D. ; Espinoza, Luis R. ; Alamino, Rodolfo Perez ; Dowell, Sharon ; Garcia-Vallardes, Ignacio ; Lawrence-Ford, Theresa ; Godoy, Adrian ; Ince, Akgun ; Flower, Cindy
ISI:000325359205205
ISSN: 0004-3591
CID: 656622
Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behcet's Syndrome (BS) [Meeting Abstract]
Sibley, Cailin ; Hatemi, Gulen ; Yazici, Yusuf ; Liu, Yin ; Brooks, Steve ; Yazici, Hasan ; Goldbach-Mansky, Raphaela
ISI:000325359203149
ISSN: 0004-3591
CID: 656472
Apremilast For The Treatment Of Behcet's Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study [Meeting Abstract]
Hatemi, Gulen ; Melikoglu, Melike ; Tunc, Recep ; Korkmaz, Cengiz ; Ozturk, Banu Turgut ; Mat, Cem ; Merkel, Peter A. ; Calamia, Kenneth ; Liu, Ziqi ; Pineda, Lilia ; Stevens, Randall M. ; Yazici, Hasan ; Yazici, Yusuf
ISI:000325359202266
ISSN: 0004-3591
CID: 656452
Prediction Of Week 52 Treatment Response Based On A Week 12 Assessment In Rheumatoid Arthritis Patients Receiving Certolizumab Pegol: Comparison Of A Patient-Reported Instrument Versus Physician-Based Disease Activity Assessment [Meeting Abstract]
Curtis, Jeffrey R. ; Koetse, Willem ; Tambiah, Jeymi ; Ionescu, Lucian ; Yazici, Yusuf
ISI:000325359201430
ISSN: 0004-3591
CID: 656392
Remission, low disease activity, and associated changes in physical function and radiographic outcomes with subcutaneous abatacept or adalimumab: results from the AMPLE trial [Meeting Abstract]
Fleischmann, R.; Schiff, M.; Weinblatt, M.; Maldonado, M.; Massarotti, E.; Yazici, Y.
ISI:000331709100195
ISSN: 0340-1855
CID: 867642
Documenting the value of care for rheumatoid arthritis, analogous to hypertension, diabetes, and hyperlipidemia: is control of individual patient self-report measures of global estimate and physical function more valuable than laboratory tests, radiographs, indices, or remission criteria?
Pincus, Theodore; Castrejon, Isabel; Yazici, Yusuf
PMID: 23996992
ISSN: 0315-162x
CID: 519542
Combination therapy in rheumatoid arthritis: Always the best option?
Bata, Y; Yazici, Y
One of the major developments in the treatment of rheumatoid arthritis over the last decade and a half has been the realization that early and aggressive treatment leads to better outcomes for most patients. Early use of methotrexate and switching to a combination treatment regimen within the first 3-6 months if there is inadequate response to methotrexate is the currently accepted paradigm for rheumatoid arthritis treatment. To achieve better outcomes it is not enough to just use combination treatments; disease activity also needs to be measured and monitored with a 'treat-to-target' approach, where remission or low disease activity is the target and available medications are used either alone or in combination to get there. 2013 Future Medicine Ltd
EMBASE:2013538626
ISSN: 1758-4272
CID: 550202